Impact of plasminogen activator inhibitor-1 gene polymorphisms on primary membranous nephropathy

Nephrology Dialysis Transplantation

Volumn 23, Issue 10, 2008, Pages 3166-3173

  Chen, Cheng Hsu ^a,b,d,e,g   Shu, Kuo Hsiung ^a,e   Wen, Mei Chin ^a,d   Chen, Kuo Jung ^a,e   Cheng, Chi Hung ^a,d,e   Lian, Jong Da ^e   Wu, Ming Ju ^a,e,f   Yu, Tung Min ^a   Tsai, Fuu Jen ^b,c  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d HUNGKUANG UNIVERSITY   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

^g TUNGHAI UNIVERSITY   (Taiwan)

Author keywords

Cardiovascular events; Gene polymorphism; Malignancy; Plasminogen activator inhibitor; Primary membranous nephropathy

Indexed keywords

CREATININE; IMMUNOSUPPRESSIVE AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ALLELES; BASE SEQUENCE; CASE-CONTROL STUDIES; COHORT STUDIES; CORONARY ARTERY DISEASE; CREATININE; DNA PRIMERS; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 52449108058     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn258     Document Type: Article

References (20)

1. Short C, Mallick N. Membranous nephropathy. In: SG Massry and RJ Glassock (ed). Massry & Glassock's Textbook of Nephrology. Baltimore, USA: Williams & Wilkins Press 2001; 726-734
2. Wu TH, Tsai CY, Yang WC. Excessive expression of the tumor necrosis factor-α gene in the kidneys of patients with membranous glomerulonephropathy. Chin Med J (Taipei) 1998; 61: 524-530
3. Banis C, Heering PJ, Aker S et al. Tumor necrosis factor-alpha gene G-308A polymorphism is a risk factor for the development of membranous glomerulonephritis. Am J Nephrol 2006; 26: 12-15
4. Cattran DC. Idiopathic membranous glomerulonephritis. Kidney Int 2001; 59: 1983-1994
5. Stratta P, Bermond F, Guarrera S et al. Interaction between gene polymorphisms of nitric oxide synthase and renin-angiotensin system in the progression of membranous glomerulonephritis. Nephrol Dial Transplant 2004; 19: 587-595
6. Wehrmann M, Bohle A, Bogenschutz O et al. Long-term prognosis of chronic idiopathic membranous glomerulonephritis. An analysis of 334 cases with particular regard to tubulointerstitial change. Clin Nephrol 1989; 31: 67-76
7. Yamamoto K, Loskutoff DJ, Saito H. Renal expression of fibrinolytic genes and tissue factor in a murine model of renal disease as a function of age. Semin Thromb Heamost 1998; 24: 261-268
8. Rerolle JP, Hertig A, Nguyen G et al. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 2000; 58: 1841-1850
9. Bao L, Zhou J, Holers VM et al. Excessive matrix accumulation in the kidneys of MRL/lpr lupus mice is dependent on complement activation. J Am Soc Nephrol 2003; 14: 2516-2525
10. Eriksson P, van Kallin BT, Hooft FM et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-1855
11. Hamano K, Iwano M, Akai Y et al. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis 2002; 39: 695-705
12. Falk G, Svensson H, Almqvist A et al. Allele specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene. Fibrinolysis 1994; 8 (S1): S45-S47
13. Mikkelsson J, Perola M, Wartiovaara U et al. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction inmiddle-aged Finnish men who died suddenly. Thromb Haemost 2000; 84: 78-82
14. Ye S, Green FR, Scarabin PY et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude Cas Temoins de l'Infarctus du Mycocarde. Thromb Haemost 1995; 74: 837-841
15. Dawson SJ, Wiman B, Hamsten A et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to Interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-10745
16. Krag S, Danielsen CC, Cameliet P et al. Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-beta-1-induced kidney disease. Kidney Int 2005; 68: 2651-2666
17. Wang AY, Poon P, Lai FM et al. Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients. Kidney Int 2001; 59: 1520-1528
18. Suzuki H, Sakuma Y, Kanesaki Y et al. Close relationship of plasminogen activator inhibitor-1 4G/5G polymorphism and progression of IgA nephropathy. Clin Nephrol 2004; 62: 173-179
19. Kimura H, Gejyo F, Suzuki Y et al. Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy. Kidney Int 1998; 54: 1659-1669
20. Kimura H, Gejyo F, Suzuki Y et al. Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy. Kidney Int 1998; 54: 1659-1669